AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1

Current Cancer Drug Targets

Volumn 14, Issue 8, 2014, Pages 700-712

  Schrader, Alexandra ^a   Popa, Wagma ^a   Lilienthal, Nils ^a   Crispatzu, Giuliano ^a   Mayer, Petra ^a   Jones, Dan ^b   Hallek, Michael ^a   Herling, Marco ^a,b  

^a Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

AKT; CLL; Inhibitor response; mTOR; PI3K; TCL1

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; A 443654; DACTOLISIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN KINASE ZAP 70; RAPAMYCIN; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; ONCOPROTEIN; TARGET OF RAPAMYCIN KINASE; TCL1A PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NORMAL HUMAN; ONCOGENE; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; T CELL LEUKEMIA 1 ONCOGENE; B LYMPHOCYTE; METABOLISM; PHYSIOLOGY;

B-LYMPHOCYTES; CELL SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84919724622     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666141028101711     Document Type: Article

References (55)

1. Hallek, M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematology Am. Soc. Hematol. Educ. Program, 2013, 2013, 138-150.
2. Davids, M.S.; Brown, J.R. Phosphoinositide 3’-kinase inhibition in chronic lymphocytic leukemia. Hematol. Oncol. Clin. North Am., 2013, 27, 329-339.
3. Zhang, S.; Kipps, T.J. The pathogenesis of chronic lymphocytic leukemia. Annu. Rev. Pathol., 2014, 9, 103-118.
4. Rossi, D.; Ciardullo, C.; Spina, V.; Gaidano, G. Molecular bases of chronic lymphocytic leukemia in light of new treatments. Immunol. Lett., 2013, 155, 51-55.
5. Burger, J.A.; Ghia, P.; Rosenwald, A.; Caligaris-Cappio, F. The microenvironment in mature B-cell malignancies: A target for new treatment strategies. Blood, 2009, 114, 3367-3375.
6. Longo, P.G.; Laurenti, L.; Gobessi, S.; Sica, S.; Leone, G.; Efremov, D.G. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood, 2008, 111, 846-855.
7. Burger, J.A.; Chiorazzi, N. B Cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol., 2013, 34, 592-601.
8. Dühren-von Minden, M.; Übelhart, R.; Schneider, D.; Wossning, T.; Bach, M.P.; Buchner, M.; Hofmann, D.; Surova, E.; Follo, M.; Köhler, F.; Wardemann, H.; Zirlik, K.; Veelken, H.; Jumaa, H. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature, 2012, 489, 309-312.
9. Quesada, V.; Conde, L.; Villamor, N.; Ordóñez, G.R.; Jares, P.; Bassaganyas, L.; Ramsay, A.J.; Beà, S.; Pinyol, M.; Martínez- Trillos, A.; López-Guerra, M.; Colomer, D.; Navarro, A.; Baumann, T.; Aymerich, M.; Rozman, M.; Delgado, J.; Giné, E.; Hernández, J.M.; González-Díaz, M.; Puente, D.A.; Velasco, G.; Freije, J.M.; Tubío, J.M.; Royo, R.; Gelpí, J.L.; Orozco, M.; Pisano, D.G.; Zamora, J.; Vázquez, M.; Valencia, A.; Himmelbauer, H.; Bayés, M.; Heath, S.; Gut, M.; Gut, I.; Estivill, X.; López-Guillermo, A.; Puente, X.S.; Campo, E.; López-Otín, C. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet., 2012, 44, 47-52.
10. Sakai, A.; Thieblemont, C.; Wellmann, A.; Jaffe, E.S.; Raffeld, M. PTEN gene alterations in lymphoid neoplasms. Blood, 1998, 92, 3410-3415.
11. Zenz, T.; Döhner, K.; Denzel, T.; Döhner, H.; Stilgenbauer, S.; Bullinger, L. Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations. Br. J. Haematol., 2008, 141, 742-743.
12. Mahmoud, I.S.; Sughayer, M.A.; Mohammad, H.A.; Awidi, A.S.; EL-Khateeb, M.S.; Ismail, S.I. The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. Br. J. Cancer, 2008, 99, 488-490.
13. Brown, J.R.; Hanna, M.; Tesar, B.; Werner, L.; Pochet, N.; Asara, J.M.; Wang, Y.E.; Dal Cin, P.; Fernandes, S.M.; Thompson, C.; Macconaill, L.; Wu, C.J.; Van de Peer, Y.; Correll, M.; Regev, A.; Neuberg, D.; Freedman, A.S. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin. Cancer Res., 2012, 18, 3791-3802.
14. De Frias, M.; Iglesias-Serret, D.; Cosialls, A.M.; Coll-Mulet, L.; Santidrián, A.F.; González-Gironès, D.M.; de la Banda, E.; Pons, G.; Gil, J. Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica, 2009, 94, 1698-1707.
15. Zhuang, J.; Hawkins, S.F.; Glenn, M.A.; Lin, K.; Johnson, G.G.; Carter, A.; Cawley, J.C.; Pettitt, A.R. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: The therapeutic potential of Akt inhibition. Haematologica, 2010, 95, 110-118.
16. Niedermeier, M.; Hennessy, B.T.; Knight, Z.A.; Henneberg, M.; Hu, J.; Kurtova, A.V; Wierda, W.G.; Keating, M.J.; Shokat, K.M.; Burger, J.A. Isoform-selective phosphoinositide 3’-kinase inhibitors inhibit cxcr4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: A novel therapeutic approach. Blood, 2009, 113, 5549-5557.
17. Brown, J.R.; Byrd, J.C.; Coutre, S.E.; Benson, D.M.; Flinn, I.W.; Wagner-Johnston, N.D.; Spurgeon, S.E.; Kahl, B.S.; Bello, C.; Webb, H.K.; Johnson, D.M.; Peterman, S.; Li, D.; Jahn, T.M.; Lannutti, B.J.; Ulrich, R.G.; Yu, A.S.; Miller, L.L.; Furman, R.R. Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood, 2014, 123, 3390-3397.
18. Foukas, L.C.; Berenjeno, I.M.; Gray, A.; Khwaja, A.; Vanhaesebroeck, B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl. Acad. Sci. U.S.A., 2010, 107, 11381-11386.
19. Herling, M.; Patel, K.A.; Weit, N.; Lilienthal, N.; Hallek, M.; Keating, M.J.; Jones, D. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood, 2009, 114, 4675-4686.
20. Pekarsky, Y.; Koval, A.; Hallas, C.; Bichi, R.; Tresini, M.; Malstrom, S.; Russo, G.; Tsichlis, P.; Croce, C.M. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 3028-3033.
21. Laine, J.; Künstle, G.; Obata, T.; Sha, M.; Noguchi, M. The protooncogene TCL1 Is an Akt kinase coactivator. Mol. Cell, 2000, 6, 395-407.
22. Bichi, R.; Shinton, S.A.; Martin, E.S.; Koval, A.; Calin, G.A.; Cesari, R.; Russo, G.; Hardy, R.R.; Croce, C.M. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 6955-6960.
23. Herling, M.; Patel, K.A; Khalili, J.; Schlette, E.; Kobayashi, R.; Medeiros, L.J.; Jones, D. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia, 2006, 20, 280-285.
24. Pekarsky, Y.; Palamarchuk, A.; Maximov, V.; Efanov, A.; Nazaryan, N.; Santanam, U.; Rassenti, L.; Kipps, T.; Croce, C.M. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 19643-19648.
25. Sivina, M.; Hartmann, E.; Vasyutina, E.; Boucas, J.M.; Breuer, A.; Keating, M.J.; Wierda, W.G.; Rosenwald, A.; Herling, M.; Burger, J.A. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia, 2012, 26, 1812-1820.
26. Hallek, M.; Cheson, B.D.; Catovsky, D.; Caligaris-Cappio, F.; Dighiero, G.; Döhner, H.; Hillmen, P.; Keating, M.J.; Montserrat, E.; Rai, K.R.; Kipps, T.J. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood, 2008, 111, 5446-5456.
27. Gharbi, S.I.; Zvelebil, M.J.; Shuttleworth, S.J.; Hancox, T.; Saghir, N.; Timms, J.F.; Waterfield, M.D. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J., 2007, 404, 15-21.
28. Fan, Q.; Knight, Z.A.; Goldenberg, D.D.; Yu, W.; Keith, E.; Stokoe, D.; Shokat, K.M.; Weiss, W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 2010, 9, 341-349.
29. Maira, S.-M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chène, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; García-Echeverría, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-Kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther., 2008, 7, 1851-1863.
30. Gopal, A.K.; Kahl, B.S.; de Vos, S.; Wagner-Johnston, N.D.; Schuster, S.J.; Jurczak, W.J.; Flinn, I.W.; Flowers, C.R.; Martin, P.; Viardot, A.; Blum, K.A.; Goy, A.H.; Davies, A.J.; Zinzani, P.L.; Dreyling, M.; Johnson, D.; Miller, L.L.; Holes, L.; Li, D.; Dansey, R.D.; Godfrey, W.R.; Salles, G.A. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med., 2014, 140122140218007.
31. Garcia-Echeverria, C.; Sellers, W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene, 2008, 27, 5511-5526.
32. Said, J.W.; Hoyer, K.K.; French, S.W.; Rosenfelt, L.; Garcia- Lloret, M.; Koh, P.J.; Cheng, T.C.; Sulur, G.G.; Pinkus, G.S.; Kuehl, W.M.; Rawlings, D.J.; Wall, R.; Teitell, M.A. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab. Invest., 2001, 81, 555-564.
33. Herling, M.; Rassidakis, G.Z.; Vassilakopoulos, T.P.; Medeiros, L. J.; Sarris, A.H.; on behalf of the International Hodgkin Lymphoma Study Group; Jarrett, R.F.; Stark, G.L.; White, J.; Angus, B.; Alexander, F.E.; Krajewski, A.S.; Freeland, J.; Taylor, G.M.; Taylor, P.R.A. Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical hodgkin lymphoma. Blood, 2006, 107, 1240-1241.
34. Warner, K.; Weit, N.; Crispatzu, G.; Admirand, J.; Jones, D.; Herling, M. T-cell receptor signaling in peripheral T-Cell lymphoma - a review of patterns of alterations in a central growth regulatory pathway. Curr. Hematol. Malig. Rep., 2013, 8, 163-172.
35. Herling, M.; Patel, K.A.; Teitell, M.A.; Konopleva, M.; Ravandi, F.; Kobayashi, R.; Jones, D. High TCL1 expression and intact Tcell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood, 2008, 111, 328-337.
36. Han, E.K.-H.; Leverson, J.D.; McGonigal, T.; Shah, O.J.; Woods, K.W.; Hunter, T.; Giranda, V.L.; Luo, Y. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene, 2007, 26, 5655-5661.
37. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307, 1098-1101.
38. Sabatini, D.M. mTOR and cancer: Insights into a complex relationship. Nat. Rev. Cancer, 2006, 6, 729-734.
39. Kurtova, A.V; Balakrishnan, K.; Chen, R.; Ding, W.; Schnabl, S.; Quiroga, M.P.; Sivina, M.; Wierda, W.G.; Estrov, Z.; Keating, M. J.; Shehata, M.; Jäger, U.; Gandhi, V.; Kay, N.E.; Plunkett, W.; Burger, J.A. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: Development of a reliable and reproducible system to assess stromal cell adhesionmediated drug resistance. Blood, 2009, 114, 4441-4450.
40. Shehata, M.; Schnabl, S.; Demirtas, D.; Hilgarth, M.; Hubmann, R.; Ponath, E.; Badrnya, S.; Lehner, C.; Hoelbl, A.; Duechler, M.; Gaiger, A.; Zielinski, C.; Schwarzmeier, J.D.; Jaeger, U. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3- K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood, 2010, 116, 2513-2521.
41. Johnson, A.J.; Lucas, D.M.; Muthusamy, N.; Smith, L.L.; Edwards, R.B.; De Lay, M.D.; Croce, C.M.; Grever, M.R.; Byrd, J.C. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood, 2006, 108, 1334-1338.
42. Zanesi, N.; Aqeilan, R.; Drusco, A.; Kaou, M.; Sevignani, C.; Costinean, S.; Bortesi, L.; La Rocca, G.; Koldovsky, P.; Volinia, S.; Mancini, R.; Calin, G.; Scott, C.P.; Pekarsky, Y.; Croce, C.M. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res., 2006, 66, 915-920.
43. Ropars, V.; Despouy, G.; Stern, M.-H.; Benichou, S.; Roumestand, C.; Arold, S.T. The TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB. PLoS One, 2009, 4, e6567.
44. Hiromura, M.; Okada, F.; Obata, T.; Auguin, D.; Shibata, T.; Roumestand, C.; Noguchi, M. Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1. J. Biol. Chem., 2004, 279, 53407-53418.
45. Akinleye, A.; Avvaru, P.; Furqan, M.; Song, Y.; Liu, D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J. Hematol. Oncol., 2013, 6, 88.
46. Zent, C.; LaPlant, B.; Johnston, P. Lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer, 2010, 116, 2201-2207.
47. Decker, T.; Sandherr, M.; Goetze, K.; Oelsner, M.; Ringshausen, I.; Peschel, C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann. Hematol., 2009, 88, 221-227.
48. Matutes, E.; Bosanquet, A.G.; Wade, R.; Richards, S.M.; Else, M.; Catovsky, D. The use of individualized tumor response testing in treatment selection: Second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry. Leukemia, 2013, 27, 507-510.
49. Tyner, J.W.; Yang, W.F.; Bankhead, A.; Fan, G.; Fletcher, L.B.; Bryant, J.; Glover, J.M.; Chang, B.H.; Spurgeon, S.E.; Fleming, W. H.; Kovacsovics, T.; Gotlib, J.R.; Oh, S.T.; Deininger, M.W.; Zwaan, C.M.; Den Boer, M.L.; van den Heuvel-Eibrink, M.M.; O’Hare, T.; Druker, B.J.; Loriaux, M.M. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res., 2013, 73, 285-296.
50. Basu, A.; Bodycombe, N.E.; Cheah, J.H.; Price, E.V; Liu, K.; Schaefer, G.I.; Ebright, R.Y.; Stewart, M.L.; Ito, D.; Wang, S.; Bracha, A.L.; Liefeld, T.; Wawer, M.; Gilbert, J.C.; Wilson, A.J.; Stransky, N.; Kryukov, G.V; Dancik, V.; Barretina, J.; Garraway, L.A.; Hon, C. S.-Y.; Munoz, B.; Bittker, J.A.; Stockwell, B.R.; Khabele, D.; Stern, A.M.; Clemons, P.A.; Shamji, A.F.; Schreiber, S.L. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell, 2013, 154, 1151-1161.
51. Garnett, M.J.; Edelman, E.J.; Heidorn, S.J.; Greenman, C.D.; Dastur, A.; Lau, K.W.; Greninger, P.; Thompson, I.R.; Luo, X.; Soares, J.; Liu, Q.; Iorio, F.; Surdez, D.; Chen, L.; Milano, R.J.; Bignell, G.R.; Tam, A.T.; Davies, H.; Stevenson, J.A.; Barthorpe, S.; Lutz, S.R.; Kogera, F.; Lawrence, K.; McLaren-Douglas, A.; Mitropoulos, X.; Mironenko, T.; Thi, H.; Richardson, L.; Zhou, W.; Jewitt, F.; Zhang, T.; O’Brien, P.; Boisvert, J.L.; Price, S.; Hur, W.; Yang, W.; Deng, X.; Butler, A.; Choi, H.G.; Chang, J.W.; Baselga, J.; Stamenkovic, I.; Engelman, J.A.; Sharma, S.V; Delattre, O.; Saez-Rodriguez, J.; Gray, N.S.; Settleman, J.; Futreal, P.A.; Haber, D.A.; Stratton, M.R.; Ramaswamy, S.; McDermott, U.; Benes, C.H. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature, 2012, 483, 570-575.
52. Fiorcari, S.; Brown, W.S.; McIntyre, B.W.; Estrov, Z.; Maffei, R.; O’Brien, S.; Sivina, M.; Hoellenriegel, J.; Wierda, W.G.; Keating, M.J.; Ding, W.; Kay, N.E.; Lannutti, B.J.; Marasca, R.; Burger, J.A. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One, 2013, 8, e83830.
53. Willems, L.; Tamburini, J.; Chapuis, N.; Lacombe, C.; Mayeux, P.; Bouscary, D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr. Oncol. Rep., 2012, 14, 129-138.
54. Kepp, O.; Galluzzi, L.; Lipinski, M.; Yuan, J.; Kroemer, G. Cell death assays for drug discovery. Nat. Rev. Drug Discov., 2011, 10, 221-237.
55. Martelli, A.M.; Evangelisti, C.; Chappell, W.; Abrams, S.L.; Bäsecke, J.; Stivala, F.; Donia, M.; Fagone, P.; Nicoletti, F.; Libra, M.; Ruvolo, V.; Ruvolo, P.; Kempf, C.R.; Steelman, L.S.; McCubrey, J.A. Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia, 2011, 25, 1064-1079.